T-CEPTOR
LIVE

Serial Number

98081098

Owner

T-Therapeutics Limited

Attorney

Stacy J. Grossman

Filing Date

Jul 12, 2023

Add to watchlist:

No watchlists yet
View on USPTO

T-CEPTOR Trademark

Serial Number: 98081098 • Registration: 7683956

T-CEPTOR is a trademark filed by T-Therapeutics Limited on July 12, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

T-Therapeutics Limited (7 trademarks)

Abington Hall, Granta Park
Cambridge CB216AL , GB

Entity Type: 99

Trademark Details

Filing Date

July 12, 2023

Registration Date

February 11, 2025

Published for Opposition

December 24, 2024

Goods & Services

Pharmaceutical preparations for protection from and prevention of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; chemical and biological pharmaceutical preparations for medical purposes, namely, for protection from and prevention of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; chemical preparations for use in DNA analysis for medical purposes; DNA synthesis inhibitors for medical purposes, namely, pharmaceutical preparations for protection from and prevention of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; biological preparations for the treatment of cancer; biological preparations for the treatment of viral and bacterial infections; biological preparations for the treatment of autoimmune diseases; biological preparations for medical use for the treatment of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; immunotherapeutic drugs namely, pharmaceutical preparations for protection from and prevention of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; reagents for medical use; diagnostic preparations for medical use; diagnostic reagents for medical use; preparations for detecting genetic predispositions for medical purposes

Medical services; diagnostic and prognostic medical services; veterinary services; medical analysis services relating to the treatment of persons; pharmaceutical advice; medical and health care services relating to DNA, genetics, and genetic pathogen testing for diagnostic or treatment purposes; medical screening and assaying in the nature of medical laboratory analysis services relating to the treatment of persons; DNA screening for medical purposes

Scientific and technological services, namely, scientific research and development in the field of pharmaceuticals for genome engineering and biopharmaceutical drug development for protection from infections, cancer, disease or inflammation; technical research in the field of pharmaceutical studies; industrial analysis and industrial research services in the field of pharmaceuticals and genome engineering; research in the field of DNA repair technology; design and development of computer hardware and software; genetic microbiology and microbiome research for scientific research purposes; scientific research in the field of genetics and genetic engineering; clinical research in the field of pharmaceuticals, biopharmaceutical drug development and genome engineering for protection and prevention from infections, cancer, disease or inflammation; scientific research in the nature of conducting clinical trials for others; pharmaceutical research and development; development of pharmaceutical preparations and medicines; research and development services in the field of antibiotics; research and development of microorganisms and cells in the nature of guided nuclease-based biocides; scientific research in the nature of conducting clinical trials for pharmaceutical products for others; bacteriological research; scientific research for medical purposes in the field of viruses and viral diseases; biological research; scientific screening and assaying being drug screening for scientific research purposes; chemical analysis; chemical research; DNA screening for scientific research purposes; genetic testing of laboratory animals for research purposes; biochemical engineering services being biochemical research and development; providing medical and scientific research information about the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing scientific research information in the field of pharmaceuticals and scientific research consulting in the field of pharmaceuticals

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 28, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 28, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 28, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 28, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 28, 2025 COAR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 11, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 11, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 24, 2024 NPUB
PUBLISHED FOR OPPOSITION
Dec 24, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 18, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Nov 26, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Nov 22, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Nov 22, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Nov 22, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Nov 22, 2024 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Nov 13, 2024 GNFN
FINAL REFUSAL E-MAILED
Nov 13, 2024 GNFR
FINAL REFUSAL WRITTEN
Nov 13, 2024 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 9, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 9, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 9, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 10, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jul 10, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jul 10, 2024 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 11, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 11, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 11, 2024 TROA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 31, 2024 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 31, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 31, 2024 COAR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 27, 2024 TCCA
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 27, 2024 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 27, 2024 COAR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 23, 2024 GNRN
NON-FINAL ACTION E-MAILED
Mar 23, 2024 GNRT
NON-FINAL ACTION WRITTEN
Mar 23, 2024 CNRT
ASSIGNED TO EXAMINER
Mar 20, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 10, 2023 NWOS
NEW APPLICATION ENTERED
Jul 15, 2023 NWAP